Related Experiment Video
Updated: Apr 4, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the
Vincent Corvari1, Linda O Narhi2, Thomas M Spitznagel3
1Eli Lilly and Company, Indianapolis, IN, USA.
Abstract:
Measurement and characterization of subvisible particles (including proteinaceous and non-proteinaceous particulate matter) is an important aspect of the pharmaceutical development process for biotherapeutics. Health authorities have increased expectations for subvisible particle data beyond criteria specified in the pharmacopeia and covering a wider size range. In addition, subvisible particle data is being requested for samples exposed to various stress conditions and to support process/product changes. Consequently, subvisible particle analysis has expanded beyond routine testing of finished dosage forms using traditional compendial methods. Over the past decade, advances have been made in the detection and understanding of subvisible particle formation. This article presents industry case studies to illustrate the implementation of strategies for subvisible particle analysis as a characterization tool to assess the nature of the particulate matter and applications in drug product development, stability studies and post-marketing changes.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
18:46Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Related Concept Videos
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioavailability Enhancement: Drug Solubility Enhancement
Factors Influencing Drug Absorption: Drug Dissolution